In Perrigo Sales Corp. v. Harris, Slip Opinion No. 2026-Ohio-3648, the Ohio Supreme Court (Court) unanimously held that the Ohio commercial activity tax (CAT) is imposed only on amounts actually received by a prescription drug manufacturer and does not include amounts contractually reduced through pharmaceutical industry "chargebacks." The Court affirmed the Board of Tax Appeals (BTA), rejecting the Tax Commissioner's position that gross receipts should be measured by the gross invoice amount.¹

Background

The taxpayer, a prescription drug manufacturer, sells its products to wholesale distributors, who in turn sell them to large retail pharmacy chains. The taxpayer invoices distributors at a "wholesale acquisition cost" or list price, while separately negotiating direct pricing agreements with downstream retailers at prices that are typically lower. When distributors sell the drugs to retailers, they remit to the taxpayer only the retailer-negotiated price, deducting the difference between that price and the retail price as a "chargeback." The taxpayer is contractually obligated to honor these chargebacks. They are not discretionary refunds, post-sale rebates or expenses.²

Following an audit, the Ohio Department of Taxation (Department) concluded the taxpayer had underreported its gross receipts for CAT purposes by reporting only the amounts received from distributors rather than the full list prices and assessed additional CAT on the chargeback amounts. On appeal, the BTA reversed the assessment, holding that the CAT applies to the "amount realized" by the taxpayer and the taxpayer never realized the chargeback portion of the invoice price. The Tax Commissioner appealed the BTA's decision to the Court.

Court's ruling

The Court's analysis turned on the CAT's definition of "gross receipts." Under R.C. 5751.02(A), the CAT is levied on "gross receipts" from doing business in Ohio. R.C. 5751.01(F) defines gross receipts as "the total amount realized by a person, without deduction for the cost of goods sold or other expenses incurred, that contributes to the production of gross income of the person."

The Court observed that the Ohio Revised Code does not separately define "amount realized"; however, R.C. 5751.01(K) provides that undefined terms carry the same meaning as under comparable federal income tax law. Under IRC Section 1001(b), "amount realized" is defined as "the sum of any money received plus the fair market value of the property (other than money) received." Accordingly, the Court concluded that the list price invoiced to distributors is not the "amount realized" for CAT purposes.

According to the Court, the taxpayer never receives the full list price because the chargeback is deducted simultaneously with payment and represents a pre-payment adjustment, rather than a post-sale refund or rebate. Moreover, the Court found that, contrary to the Department's argument, the chargebacks are not an "expense" or a cost of goods sold "deduction" from gross receipts; rather "they were simply an accounting entry necessary to reflect the amount that [the taxpayer] actually realized on the transactions."

In affirming the BTA, the Court rejected six propositions of law raised by the Department, finding none of them persuasive. These arguments included (1) the BTA improperly equated Ohio "gross receipts" with federal "gross income," (2) allowing exclusion of chargebacks violates Ohio's no-deduction rule (R.C. 5751.01(F)) because chargebacks are "expenses of doing business," and (3) the BTA's interpretation renders certain statutory exclusions (e.g., cash discounts allowed and taken, returns and allowances) superfluous.

Implications

The Court's decision validates the reporting position taken by pharmaceutical manufacturers that have excluded chargebacks from their CAT gross receipts base. Taxpayers in the industry may want to consider reviewing any open CAT audits, assessments or refund opportunities where the Tax Commissioner has asserted the list-price-based theory to include chargebacks in gross receipts. The decision may have broader significance outside the pharmaceutical industry. The Court's analysis is grounded in what constitutes an "amount realized," emphasizing CAT gross receipts are limited to the amount of money actually received. Businesses that employ contractual pre-payment offsets, trade netting, industry-standard price adjustments or similar mechanisms should consider examining whether the same framework might apply to their CAT compliance.